Atlas market file · Equity · United States
Cytek Biosciences, Inc.CTKB
- Last close
- 4.16
- Change
- -0.48%
- 96-bar range
- 3.31 – 4.99
- As of
- 6 Aug 2026
Cytek Biosciences, Inc. is a laboratory analytical instruments issuer listed as CTKB on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
CTKB
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-26.37% over the window).
Source rail: Yahoo Finance chart API (CTKB). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for CTKB. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
CTKB public profile
Laboratory analytical instruments issuer. Cytek Biosciences, Inc. is connected to current market context, cited company sources and its retained research file.
Cytek Biosciences, Inc. trades as CTKB on NASDAQ. Cytek Biosciences, Inc. (CTKB) has a latest verified close of 4.16, down 0.48%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files CTKB under USA Stocks and Science & Biotech Stocks for browsing.
What changed for Cytek Biosciences, Inc. today
Cytek Biosciences (CTKB) reported a net loss of $18.9M and negative operating cash flow of $2.7M in Q1 2026, despite opening a new innovation center in Bellevue, Washington, and unveiling next-gen spectral flow cytometry systems at CYTO 2026. The company’s inventory increased to $49.8M, up $1.6M from prior periods, while R&D expenses held steady at $9.6M. (source: SEC EDGAR 10-Q, period ending 2026-03-31)
Cytek’s core business revolves around high-end flow cytometry systems like the Aurora and Borealis platforms, which target research institutions and clinical labs in China and the EU. However, its reliance on a narrow product suite and unproven ability to forecast demand creates operational risk. The company’s cash reserves ($65.7M) are offset by $121.5M in liabilities, leaving equity at $327.6M. (source: Cytek Biosciences product page, https://www.cytekbio.com/blogs/news/cytek-biosciences-to-unveil-next-generation-spectral-flow-cytometry-innovations-at-cyto-2026)
Recent filings highlight insider share sales and executive compensation tied to ‘transition support’ at $1,000/hour, even as the company issues new shares (diluted count: 128.7M). A 7-laser Borealis system launch and Bellevue facility relocation aim to boost R&D and customer engagement, but the market will watch whether these moves translate to revenue growth or further cash burn. (source: SEC EDGAR 8-K, 2026-07-15, https://www.sec.gov/Archives/edgar/data/1831915/000119312526304789/d99130d8k.htm)
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
CTKB technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on CTKB
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep CTKB research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
CTKB FAQ
What is Cytek Biosciences, Inc. (CTKB)?Cytek Biosciences, Inc. (CTKB) has a latest verified close of 4.16, down 0.48%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
Cytek Biosciences, Inc. (CTKB) has a latest verified close of 4.16, down 0.48%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for CTKB?Cytek Biosciences, Inc. (CTKB) has a latest verified close of 4.16, down 0.48%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources,...
Cytek Biosciences, Inc. (CTKB) has a latest verified close of 4.16, down 0.48%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files CTKB under USA Stocks and Science & Biotech Stocks for browsing.
How often is the CTKB page updated?The CTKB public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The CTKB public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for CTKB?The CTKB file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CTKB. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The CTKB file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:CTKB. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on CTKB?Yes. The workstation can open CTKB, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open CTKB, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this CTKB page investment advice?No. The CTKB page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The CTKB page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →